Track record · closed signal

Harmony Biosciences Holdings Inc. (HRMY) — closed signal from July 7, 2025

Partial Published before the outcome was known, scored automatically when the window closed on October 5, 2025.

Predicted vs. what happened

HRMY price · publication thesis → realized outcomesplit-adjusted
$32.49 Published $42.23 Target $27.28 Window close $38.28 Peak
$31.00 – $33.00Entry zone — fair-value band
$32.49Published — price the day we called it
$42.23Target — the price the thesis aimed for
$38.28Peak — highest point inside the window, not a realized return
$27.28Window close — end-of-window price, context only

What happened

Partial

Reached 59% of the predicted growth at its peak, without hitting the target.

Peak price
$38.28
peak on August 27, 2025 — not a realized return
Peak gain
+17.8%
peak, from the publication price
Window close
$27.28
end-of-window price, context only
Days to target
—
Window
July 7, 2025 – October 5, 2025

The thesis — published July 7, 2025

Predicted growth
+30%
over the measurement window
Target price
$42.23
the price the thesis aimed for
Entry zone
$31.00 – $33.00
the fair-value band we waited for
Price at publication
$32.49
published July 7, 2025
Confidence
70%
how strongly the data lined up
Timeframe
Short-term (0–3 months)

A big make-or-break study is due by September. Wakix sales are still rising about 20 percent, giving cash for research and limiting losses. Recent media coverage gave the stock a perfect sentiment score, calling it a new cannabis idea. Shares sit near 31 dollars; good results could lift them to 42-46, but bad news would likely drag them down.

Primary drivers

  • Fragile X study results expected before October will set the next direction.
  • Wakix sales growing 20 percent provide steady cash and soften downside risk.
  • July 4 media buzz pushed sentiment to 100, attracting short-term event buyers.
  • Quiet price action hints that study news could spark a sharp move either way.

How it played out

HRMY: target missed after a partial rally

Lyra published HRMY at $32.49 on July 7, 2025, with 30 percent expected growth and a $42.23 target. The thesis pointed to Fragile X study results expected before October, Wakix sales growing 20 percent, July 4 media buzz, and quiet price action that could leave room for a sharp move.

Inside the window, HRMY rose, but the move stopped short of the target. The stock peaked at $38.28 on August 27, a 17.8 percent gain. It never reached $42.23. By October 5, it ended at $27.28. The thesis partially played out, then missed the full target.

What happened during the window

On September 24, 2025, Investors.com reported that Harmony's ZYN002 missed its goal in the RECONNECT Fragile X study, which included 215 patients. The same report said HRMY fell 16.6 percent and closed at $26.76 that day.

Prices are shown split- and dividend-adjusted, matching what public charts show today.

Share this receipt

A scored call, published before the outcome was known. Paste the link anywhere — it unfurls as the card above.

Lyra

Read the next call before it closes.

This is one signal, scored after the fact. Today’s picks come with the same plain-language thesis — published before anyone knows the outcome.

See today’s picks All HRMY signals